Sugar Hydrogel Wound Dressing for Chronic Ulcer Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic wounds, such as diabetic, venous, and arterial ulcers, fail to heal due to prolonged inflammation, infection, and cellular and molecular abnormalities, leading to significant healthcare challenges and costs.
Innovation Solution
A pharmaceutical composition comprising equal parts of granulated sugar and a hydrogel biomaterial, including purified water, glycerol, hydroxyl ethyl cellulose, sodium lactate, and allantoin, is administered topically or as a dressing to promote wound healing by accelerating collagen synthesis, neovascularization, and removing fibrin, slough, and biofilm, thereby enhancing wound closure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional wound dressings are used for chronic wounds, then wound bed protection is provided, but wound closure rate remains slow due to prolonged inflammation and failure to progress through healing phases
Solution Approach 1:
The patent changes the chemical and physical parameters of the wound environment by applying a composition with specific pH (5.5-7.5), osmolarity (200-400 mOsm/L), and moisture content (10-30%). These parameter changes create optimal conditions for healing by neutralizing excessive alkalinity, regulating fluid balance, and promoting progression from inflammatory to proliferative phase
Solution Approach 2:
The patent uses a composite dressing composition combining hydrogel matrix (providing moisture retention and pH buffering), sugar (creating hyperosmolar environment to draw out excess fluid and inhibit bacteria), and allantoin (promoting epithelialization). This composite material simultaneously addresses multiple wound pathology issues
2Reliability
If the wound bed remains in prolonged inflammatory phase, then infection risk is present, but progression to granulation tissue formation and epithelialization is blocked
Solution Approach 1:
The patent applies preliminary anti-action by using the hyperosmolar sugar component to draw out excess inflammatory exudate and create an environment unfavorable for bacterial growth before infection can establish. The controlled pH and moisture levels preemptively create conditions that favor healing over inflammation
Solution Approach 2:
The patent converts the harmful prolonged inflammation into benefit by using the inflammatory exudate as a source of nutrients for the hydrogel, while simultaneously controlling its volume through osmotic action. The sugar component converts excess moisture (which could promote infection) into a controlled hyperosmolar environment that inhibits bacteria
3Productivity
If fibrin, slough, and biofilm are not removed, then wound bed is protected from further damage, but they prevent granulation tissue formation and epithelialization
Solution Approach 1:
The patent employs self-service by creating a hyperosmolar environment with sugar that draws out excess fibrin and slough through osmotic gradients, while the controlled moisture level promotes autolytic debridement. The wound bed cleans itself without requiring aggressive mechanical intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly increases wound closure rates, with average percent wound closure ranging from 50% to 100% compared to controls, effectively treating chronic non-healing wounds by promoting granulation tissue formation and epithelialization.
Implementation Method 1
accelerating collagen synthesis, neovascularization
Implementation Method 2
removing fibrin, slough, and biofilm
Implementation Method 3
A pharmaceutical composition comprising equal parts of granulated sugar and a hydrogel biomaterial
Implementation Method 4
promoting granulation tissue formation and epithelialization
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The described invention provides pharmaceutical compositions and methods for treating chronic non-healing wounds. The pharmaceutical compositions of the described invention comprise a granulated sugar and a hydrogel biomaterial.